New prospects in psychiatry, the bio-clinical interface I : edited proceedings of the bio-clinical interface conferences, held in Rouffach, France, between 1989 and 1991
著者
書誌事項
New prospects in psychiatry, the bio-clinical interface I : edited proceedings of the bio-clinical interface conferences, held in Rouffach, France, between 1989 and 1991
(Developments in psychiatry, v. 9)
Elsevier Science Publishers, 1992
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
内容説明・目次
内容説明
Based on the annual "Bio-clinical Interface" conferences, this book is an interface between a wide range of disciplines and a point of interaction between several groups of people: psychiatrists, basic scientists, as well as researchers and decision-makers from the pharmaceutical industry. The chapters provide an up-to-date synthesis of the many facets of current research in psychiatry, and is logically organized around three major themes: New Prospects in Psychopharmacology, Recent Advances in Psychiatry, and Drug Treatment in Psychiatry. The scope and variety of the book reflect the changing aspect of psychiatry, today fertilized by tools and theories from the neurosciences, and bind these many facets into a coherent whole. This close integration of several approaches tests current scientific hypotheses, and establishes a working collaboration between psychiatric research centers and the pharmaceutical industry.
目次
Section 1: New Prospects in Psychopharmacology. Neuroleptics: New molecules and their possible mechanism of action. Controlled comparison of a new triazolobenzodiazepine, adinazolam, with amitriptyline and diazepam in endogenous depressive inpatients selected from biological criteria. Psychopharmacology and psychiatric nosology. What are the diseases that can be treated by antidepressants. The use of a polydiagnostic system for the evaluation of psychotropic drugs. Clinical relevance of pharmacogenetics for psychotropic drugs. Predictive neuroendocrine markers in psychotropic drugs treatment. Modifications of sleep induced by ligands of benzodiazepine receptors: full agonists, partial agonists, and antagonists. Magnetoencephalography: basic principles, some applications, and prospects for the study of psychotropic drugs. Good clinical practices, a guarantee of quality in psychotropic drug trials. Cinical models of response to treatment, historical perspective. Treatment of disorders of the catecholaminergic system. Visual and spectral analysis of psychopharmacological sleep studies. Efficacy and tolerability of SDZ HDC 912, a dopamine D-2 agonist in the treatment of schizophrenia. New antidepressants and their possible mechanisms of action. Benzodiazepines and Buspirone: Anxiolytics and antidepressants? PET scan and antipsychotic drugs. Effects of antidepressants on sleep-EEG and nocturnal hormonal secretion, studies in depressed patients and normal controls. Section 2: Recent Advances in Psychiatry. Neurobiological models for the study of depressive disorders. Psychopharmacological models of normal aging. Pharmacogenetic polymorphism of psychotropic drug metabolism. From neurasthenia to the chronic fatigue syndrome. Multihormonal responses to a series of neuroendocrine tests in psychiatric patients. Composite diagnostic evaluation of hyperthymic disorders and its application in psychiatry. Antidepressant medication and therapeutic sleep deprivation in depressed patients. Experimental model of schizophrenia. Adult consequences of childhood separation anxiety disorder. The old and the new genetics of schizophrenia. Functional psychopathology and functional target syndromes. Pathophysiology linked to behavior therapy and psychopathology in tic disorders. A data base on the interactions between psychotropic drugs and concomitant physical disorders. Use of PET to study drugs of abuse. Measurement of drug effects on cognition. Section 3: Drug Treatment in Psychiatry Predictors of schizophrenic patients treated with neuroleptics. New methods in the development of psychotropic drugs. Drugs in psychiatry. Beyond the dichotomy of schizophrenia. Protirelin test results in antidepressant treatment of major depression. Clinical profile of selective serotonin re-uptake inhibitors. The medical model in the management of heroin dependance in a naltrexone clinic. Serotoninergic systems and depression: Approach through the learned helplessness paradigm.
「Nielsen BookData」 より